Evidence map›Paper›PMID 39779909›Full record

ArticleCell death and differentiation2025

Inactivation of GSK3β by Ser

Felipe Valença-Pereira, Ryan M Sheridan, Kent A Riemondy, Tina Thornton, Qian Fang, Brad Barret, Gabriela Paludo, Claudia Thompson, Patrick Collins, Mario Santiago and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cell death and differentiation, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Felipe Valença-PereiraDepartment of Immunology and Microbiology, University of Colorado, Anschutz Medical Campus, Aurora, CO, 80045, USA.
Ryan M SheridanDepartment of Biochemistry and Molecular Genetics, RNA Bioscience Initiative, University of Colorado, Anschutz Medical Campus, Aurora, CO, 80045, USA.
Kent A RiemondyDepartment of Biochemistry and Molecular Genetics, RNA Bioscience Initiative, University of Colorado, Anschutz Medical Campus, Aurora, CO, 80045, USA.
Tina ThorntonDepartment of Medicine, Immunobiology Division, University of Vermont, Burlington, VT, 05405, USA.
Qian FangDepartment of Immunology and Microbiology, University of Colorado, Anschutz Medical Campus, Aurora, CO, 80045, USA.
Brad BarretDivision of Infectious Diseases, Department of Medicine, University of Colorado, Anschutz Medical Campus, Aurora, CO, 80045, USA.
Gabriela PaludoDepartment of Pharmacosciences, Universidade Federal de Ciências da Saúde de Porto Alegre, Porto Alegre, RS, 90050-170, Brazil.
Claudia ThompsonDepartment of Pharmacosciences, Universidade Federal de Ciências da Saúde de Porto Alegre, Porto Alegre, RS, 90050-170, Brazil.
Patrick CollinsDepartment of Microbial Infection and Immunity, The Ohio State University, Columbus, OH, 43210, USA.
Mario SantiagoDivision of Infectious Diseases, Department of Medicine, University of Colorado, Anschutz Medical Campus, Aurora, CO, 80045, USA.
Eugene OltzDepartment of Microbial Infection and Immunity, The Ohio State University, Columbus, OH, 43210, USA.
Mercedes RinconDepartment of Immunology and Microbiology, University of Colorado, Anschutz Medical Campus, Aurora, CO, 80045, USA. mercedes.rincon@cuanschutz.edu.ORCID 0000-0002-6663-2225

Funding

P53 and cell cycle checkpoint by p38 MAP kinaseR01AI051454 · NIAID · UNIVERSITY OF VERMONT &ST AGRIC COLLEGE · PI RINCON, MERCEDES · 2003 to 2019
$4.9M
Molecular Mechanisms of Immune ToleranceT32AI074491 · NIAID · NATIONAL JEWISH HEALTH · PI CAMBIER, JOHN C, PELANDA, ROBERTA · 2009 to 2023
$4.1M
APOBEC3/Rfv3 and Immunoglobulin Somatic HypermutationR01AI116603 · NIAID · UNIVERSITY OF COLORADO DENVER · PI SANTIAGO, MARIO LUIS · 2016 to 2020
$2.5M
GSK3b and dsRNA in CD8 cellsR21AI167201 · NIAID · UNIVERSITY OF COLORADO DENVER · PI RINCON, MERCEDES · 2022 to 2023
$428k
p38 MAP kinase in early thymocyte developmentR56AI051454 · NIAID · UNIVERSITY OF VERMONT & ST AGRIC COLLEGE · PI RINCON, MERCEDES · 2008 to 2008
$376k
p53 and p38 MAP Kinase in thymocyte developmentR21AI051454 · NIAID · UNIVERSITY OF VERMONT &ST AGRIC COLLEGE · PI RINCON, MERCEDES R. · 2002 to 2002
$299k
NIAID NIH HHS R01 AI051454NIAID NIH HHS R01 AI116603NIAID NIH HHS R21 AI051454NIAID NIH HHS R21 AI167201NIAID NIH HHS R56 AI051454NIAID NIH HHS T32 AI074491U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases (NIAID) AI051454
6 · The paper itself

Abstract

The assembly of Tcrb and Tcra genes require double negative (DN) thymocytes to undergo multiple rounds of programmed DNA double-strand breaks (DSBs), followed by their efficient repair. However, mechanisms governing cell cycle checkpoints and specific survival pathways during the repair process remain unclear. Here, we report high-resolution scRNA-seq analyses of individually sorted mouse DN3 and DN4 thymocytes, which reveals a G2M cell cycle checkpoint, in addition to the known G1 checkpoint, during Tcrb and Tcra recombination. We also show that inactivation of GSK3β by phosphorylation on Ser

Indexed as

Glycogen Synthase Kinase 3 betaNecroptosisReceptors, Antigen, T-Cell, alpha-betaThymocytesAnimalsMiceMice, Inbred C57BLPhosphorylationV(D)J RecombinationGlycogen Synthase Kinase 3 betaGsk3b protein, mouseReceptors, Antigen, T-Cell, alpha-beta

Identifiers

PMID39779909
PMCPMC12089596

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.